bf/NASDAQ:IMTX_icon.png

COM:IMMATICS

Immatics

  • Stock

Last Close

9.35

05/11 21:00

Market Cap

1.25B

Beta: -

Volume Today

274.24K

Avg: -

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-...Show More

peer of

competitor of